Licensing analysis: big deals bolster biotech
PD-(L)1 x VEGF bispecifics prove a big draw.
PD-(L)1 x VEGF bispecifics prove a big draw.
Controversial nods came for Urogen’s Zusduri and Astra/Daiichi’s Datroway.
A new phase 3 could see ivonescimab challenge AstraZeneca’s Imfinzi in limited-stage disease.
Crunch time approaches for UroGen.
The company is paying $1.25bn for a PD-1 x VEGF project, the largest deal here yet.
Conference activity picks up, with the big one – ASCO – at the end of the month.